Trial Profile
A Real-World Study Comparing the Effects of Canagliflozin Versus Glucagon-Like Peptide-1 Receptor Agonists on Body Weight Outcomes in Routine Practice
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 20 Jul 2018
Price :
$35
*
At a glance
- Drugs Canagliflozin (Primary) ; Glucagon like peptide 1 receptor agonists
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 20 Jul 2018 New trial record
- 26 Jun 2018 Results presented at the 78th Annual Scientific Sessions of the American Diabetes Association.